Patents by Inventor Tillman Gerngross
Tillman Gerngross has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8815544Abstract: The present invention provides a novel lower eukaryotic host cell producing human-like glycoproteins characterized as having a terminal ?-galactose residue and essentially lacking fucose and sialic acid residues. The present invention also provides a method for catalyzing the transfer of a galactose residue from UDP-galactose onto an acceptor substrate in a recombinant lower eukaryotic host cell, which can be used as a therapeutic glycoprotein.Type: GrantFiled: July 21, 2010Date of Patent: August 26, 2014Assignee: Glycofi, Inc.Inventors: Robert Davidson, Tillman Gerngross, Stefan Wildt, Byung-Kwon Choi, Juergen Hermann Nett, Piotr Bobrowicz, Stephen Robin Hamilton
-
Patent number: 8771720Abstract: Polyhydroxyalkanoates (PHAs) from which pyrogen has been removed are provided. PHAs which have been chemically modified to enhance physical and/or chemical properties, for targeting or to modify biodegradability or clearance by the reticuloendothelial system (RES), are described. Methods for depyrogenating PHA polymers prepared by bacterial fermentation processes are also provided, wherein pyrogens are removed from the polymers without adversely impacting the polymers' inherent chemical structures and physical properties. PHAs with advantageous processing characteristics, including low melting points and/or solubility in non-toxic solvents, are also described. The PHAs are suitable for use in in vivo applications such as in tissue coatings, stents, sutures, tubing, bone, other prostheses, bone or tissue cements, tissue regeneration devices, wound dressings, drug delivery, and for diagnostic and prophylactic uses.Type: GrantFiled: July 10, 2012Date of Patent: July 8, 2014Assignee: Metabolix, Inc.Inventors: Simon F. Williams, David P. Martin, Tillman Gerngross, Daniel M. Horowitz
-
Patent number: 8231889Abstract: Polyhydroxyalkanoates (PHAs) from which pyrogen has been removed are provided for use in numerous biomedical applications. PHAs which have been chemically modified to enhance physical and/or chemical properties, for targeting or to modify biodegradability or clearance by the reticuloendothelial system (RES), are described. Methods for depyrogenating PHA polymers prepared by bacterial fermentation processes are also provided, wherein pyrogens are removed from the polymers without adversely impacting the polymers' inherent chemical structures and physical properties. PHAs with advantageous processing characteristics, including low melting points and/or solubility in non-toxic solvents, are also described. PHAs are provided which are suitable for use in in vivo applications such as in tissue coatings, stents, sutures, tubing, bone and other prostheses, bone or tissue cements, tissue regeneration devices, wound dressings, drug delivery, and for diagnostic and prophylactic uses.Type: GrantFiled: February 4, 2011Date of Patent: July 31, 2012Assignee: Metabolix, Inc.Inventors: Simon F. Williams, David P. Martin, Tillman Gerngross, Daniel M. Horowitz
-
Publication number: 20110135707Abstract: Polyhydroxyalkanoates (PHAs) from which pyrogen has been removed are provided for use in numerous biomedical applications. PHAs which have been chemically modified to enhance physical and/or chemical properties, for targeting or to modify biodegradability or clearance by the reticuloendothelial system (RES), are described. Methods for depyrogenating PHA polymers prepared by bacterial fermentation processes are also provided, wherein pyrogens are removed from the polymers without adversely impacting the polymers' inherent chemical structures and physical properties. PHAs with advantageous processing characteristics, including low melting points and/or solubility in non-toxic solvents, are also described. PHAs are provided which are suitable for use in in vivo applications such as in tissue coatings, stents, sutures, tubing, bone and other prostheses, bone or tissue cements, tissue regeneration devices, wound dressings, drug delivery, and for diagnostic and prophylactic uses.Type: ApplicationFiled: February 4, 2011Publication date: June 9, 2011Inventors: Simon F. Williams, David P. Martin, Tillman Gerngross, Daniel M. Horowitz
-
Patent number: 7906135Abstract: Polyhydroxyalkanoates (PHAs) from which pyrogen has been removed are provided for use in numerous biomedical applications. PHAs which have been chemically modified to enhance physical and/or chemical properties, for targeting or to modify biodegradability or clearance by the reticuloendothelial system (RES), are described. Methods for depyrogenating PHA polymers prepared by bacterial fermentation processes are also provided, wherein pyrogens are removed from the polymers without adversely impacting the polymers' inherent chemical structures and physical properties. PHAs with advantageous processing characteristics, including low melting points and/or solubility in non-toxic solvents, are also described. PHAs are provided which are suitable for use in vivo applications such as in tissue coatings, stents, sutures, tubing, bone and other prostheses, bone or tissue cements, tissue regeneration devices, wound dressings, drug delivery, and for diagnostic and prophylactic uses.Type: GrantFiled: May 15, 2007Date of Patent: March 15, 2011Assignee: Metabolix, Inc.Inventors: Simon F. Williams, David P. Martin, Tillman Gerngross, Daniel M. Horowitz
-
Publication number: 20090226464Abstract: The present invention relates to immunoglobulin glycoprotein compositions having predominant N-glycan structures on an immunoglobulin glycoprotein which confer a specific effector function. Additionally, the present invention relates to pharmaceutical compositions comprising an antibody having a particular enriched N-glycan structure, wherein said N-glycan structure is selected from the group consisting of Man7GlcNAc2 and Man8GlcNAc2.Type: ApplicationFiled: September 9, 2005Publication date: September 10, 2009Inventors: Tillman Gerngross, Stefan Wildt, Huijuan Li
-
Publication number: 20090136525Abstract: Compositions and methods for producing compositions comprising immunoglobulins or immunoglobulin fragments having an N-linked glycosylation pattern consisting predominantly of the GlCNAcMan3GlcNAc2 N-glycan structure are disclosed. The GlCNAcMan3GlcNAc2 N-glycan structure effects an increase in binding to the Fc?Ri? receptors and a decrease in binding to the Fc?RH receptors.Type: ApplicationFiled: September 1, 2006Publication date: May 28, 2009Inventors: Tillman Gerngross, Stefan Wildt, Huijuan Li
-
Patent number: 7479389Abstract: Novel genes encoding P. pastoris ARG1, ARG2, ARG3, HIS1, HIS2, HIS5 and HIS6 are disclosed. A method for inactivating alternately at least two biosynthetic pathways in a methylotrophic yeast is provided. A method for producing and selecting yeast strains characterized as being capable of genetic integration of heterologous sequences into the host genome using the genes involved in the biosynthetic pathways is also disclosed.Type: GrantFiled: March 2, 2005Date of Patent: January 20, 2009Assignee: GlycoFi, Inc.Inventors: Juergen Nett, Tillman Gerngross
-
Publication number: 20070280899Abstract: Polyhydroxyalkanoates (PHAs) from which pyrogen has been removed are provided for use in numerous biomedical applications. PHAs which have been chemically modified to enhance physical and/or chemical properties, for targeting or to modify biodegradability or clearance by the reticuloendothelial system (RES), are described. Methods for depyrogenating PHA polymers prepared by bacterial fermentation processes are also provided, wherein pyrogens are removed from the polymers without adversely impacting the polymers' inherent chemical structures and physical properties. PHAs with advantageous processing characteristics, including low melting points and/or solubility in non-toxic solvents, are also described. PHAs are provided which are suitable for use in vivo applications such as in tissue coatings, stents, sutures, tubing, bone and other prostheses, bone or tissue cements, tissue regeneration devices, wound dressings, drug delivery, and for diagnostic and prophylactic uses.Type: ApplicationFiled: May 15, 2007Publication date: December 6, 2007Inventors: Simon Williams, David Martin, Tillman Gerngross, Daniel Horowitz
-
Publication number: 20070178551Abstract: Cell lines having genetically modified glycosylation pathways that allow them to carry out a sequence of enzymatic reactions, which mimic the processing of glycoproteins in humans, have been developed. Recombinant proteins expressed in these engineered hosts yield glycoproteins more similar, if not substantially identical, to their human counterparts. The lower eukaryotes, which ordinarily produce high-mannose containing N-glycans, including unicellular and multicellular fungi are modified to produce N-glycans such as Man5GlcNAc2 or other structures along human glycosylation pathways.Type: ApplicationFiled: November 1, 2005Publication date: August 2, 2007Applicant: GlycoFi, Inc.Inventor: Tillman Gerngross
-
Patent number: 7244442Abstract: Polyhydroxyalkanoates (PHAs) from which pyrogen has been removed are provided for use in numerous biomedical applications. PHAs which have been chemically modified to enhance physical and/or chemical properties, for targeting or to modify biodegradability or clearance by the reticuloendothelial system (RES), are described. Methods for depyrogenating PHA polymers prepared by bacterial fermentation processes are also provided, wherein pyrogens are removed from the polymers without adversely impacting the polymers' inherent chemical structures and physical properties. PHAs with advantageous processing characteristics, including low melting points and/or solubility in non-toxic solvents, are also described. PHAs are provided which are suitable for use in in vivo applications such as in tissue coatings, stents, sutures, tubing, bone and other prostheses, bone or tissue cements, tissue regeneration devices, wound dressings, drug delivery, and for diagnostic and prophylactic uses.Type: GrantFiled: August 15, 2003Date of Patent: July 17, 2007Assignee: Metabolix, Inc.Inventors: Simon F. Williams, David P. Martin, Tillman Gerngross, Daniel M. Horowitz
-
Publication number: 20070105127Abstract: Cell lines having genetically modified glycosylation pathways that allow them to carry out a sequence of enzymatic reactions, which mimic the processing of glycoproteins in humans, have been developed. Recombinant proteins expressed in these engineered hosts yield glycoproteins more similar, if not substantially identical, to their human counterparts. The lower eukaryotes, which ordinarily produce high-mannose containing N-glycans, including unicellular and multicellular fungi are modified to produce N-glycans such as Man5GlcNAc2 or other structures along human glycosylation pathways.Type: ApplicationFiled: November 10, 2005Publication date: May 10, 2007Applicant: GlycoFi, Inc.Inventor: Tillman Gerngross
-
Publication number: 20070072262Abstract: Novel genes encoding P. pastoris ARG1, ARG2, ARG3, HIS1, HIS2, HIS5 and HIS6 are disclosed. A method for inactivating alternately at least two biosynthetic pathways in a methylotrophic yeast is provided. A method for producing and selecting yeast strains characterized as being capable of genetic stable integration of heterologous sequences into the host genome using the genes involved in the biosynthetic pathways is also disclosed.Type: ApplicationFiled: March 2, 2005Publication date: March 29, 2007Inventors: Juergen Nett, Tillman Gerngross
-
Publication number: 20070037248Abstract: The present invention relates to eukaryotic host cells, especially lower eukaryotic host cells, having modified oligosaccharides which may be modified further by heterologous expression of a set of glycosyltransferases, sugar and sugar nucleotide transporters to become host-strains for the production of mammalian, e.g., human therapeutic glycoproteins. The process provides an engineered host cell which can be used to express and target any desirable gene(s) involved in glycosylation. Host cells with modified lipid-linked oligosaccharides are created or selected. N-glycans made in the engineered host cells exhibit GnTIII, GnTIV, GnTV, GnT VI or GnTIX activity, which produce bisected and/or multiantennary N-glycan structures and may be modified further by heterologous expression of one or more enzymes, e.g., glycosyltransferases, sugar, sugar nucleotide transporters, to yield human-like glycoproteins.Type: ApplicationFiled: February 20, 2004Publication date: February 15, 2007Inventors: Piotr Bobrowicz, Stephen Hamilton, Tillman Gerngross, Stefan Wildt, Byung-Kwon Choi, Juergen Nett, Robert Davidson
-
Publication number: 20060257399Abstract: The present invention relates to immunoglobulin glycoprotein compositions having predominant N-glycan structures on an immunoglobulin glycoprotein which confer a specific effector function. Additionally, the present invention relates to pharmaceutical compositions comprising an antibody having a particular enriched N-glycan structure, wherein said N-glycan structure is Man5GlcNAc2.Type: ApplicationFiled: December 22, 2005Publication date: November 16, 2006Applicant: GlycoFi, Inc.Inventors: Tillman Gerngross, Huijuan Li, Stefan Wildt
-
Publication number: 20060252096Abstract: Disclosed are antibodies and methods for making antibodies with desired glycosylation and efficient production. Host cells transformed with a nucleic acid encoding a fusion protein comprising a signal sequence, light and heavy immunoglobulin chains, each comprising a variable region and a constant region and separated by a spacer peptide comprising at least one proteolytic cleavage site are cultured to express the nucleic acids and are cleaved by appropriate proteases to produce antibodies.Type: ApplicationFiled: April 25, 2006Publication date: November 9, 2006Applicant: GlycoFi, Inc.Inventors: Dongxing Zha, Byung-Kwon Choi, Tillman Gerngross
-
Publication number: 20060177898Abstract: Cell lines having genetically modified glycosylation pathways that allow them to carry out a sequence of enzymatic reactions, which mimic the processing of glycoproteins in humans, have been developed. Recombinant proteins expressed in these engineered hosts yield glycoproteins more similar, if not substantially identical, to their human counterparts. The lower eukaryotes, which ordinarily produce high-mannose containing N-glycans, including unicellular and multicellular fungi are modified to produce N-glycans such as Man5GlcNAc2 or other structures along human glycosylation pathways.Type: ApplicationFiled: October 11, 2005Publication date: August 10, 2006Applicant: GlycoFi, Inc.Inventor: Tillman Gerngross
-
Publication number: 20060148035Abstract: Cell lines having genetically modified glycosylation pathways that allow them to carry out a sequence of enzymatic reactions, which mimic the processing of glycoproteins in humans, have been developed. Recombinant proteins expressed in these engineered hosts yield glycoproteins more similar, if not substantially identical, to their human counterparts. The lower eukaryotes, which ordinarily produce high-mannose containing N-glycans, including unicellular and multicellular fungi are modified to produce N-glycans such as Man5GlcNAc2 or other structures along human glycosylation pathways.Type: ApplicationFiled: November 10, 2005Publication date: July 6, 2006Applicant: GlycoFi, Inc.Inventor: Tillman Gerngross
-
Publication number: 20060141570Abstract: Purification of recombinant proteins is performed by expressing in a host cell a fusion protein comprising: (a) a product protein domain, (b) an intein, and (c) at least one aggregator protein domain, wherein the aggregator protein domain comprises a protein that is capable of specific association with granules of polyhydroxyalkanoate (PHA).Type: ApplicationFiled: November 16, 2005Publication date: June 29, 2006Inventors: David Wood, Mahmoud Banki, Tillman Gerngross
-
Publication number: 20060078963Abstract: Cell lines having genetically modified glycosylation pathways that allow them to carry out a sequence of enzymatic reactions, which mimic the processing of glycoproteins in humans, have been developed. Recombinant proteins expressed in these engineered hosts yield glycoproteins more similar, if not substantially identical, to their human counterparts. The lower eukaryotes, which ordinarily produce high-mannose containing N-glycans, including unicellular and multicellular fungi are modified to produce N-glycans such as Man5GlcNAc2 or other structures along human glycosylation pathways.Type: ApplicationFiled: September 30, 2005Publication date: April 13, 2006Applicant: GlycoFi, Inc.Inventor: Tillman Gerngross